Narasimhan: Cell therapy can reset immune system, turning back autoimmune disease clock by 15-20 years
Cell therapy data shows ability to reset the immune system in severe immunological diseases, potentially delivering dramatic responses that reverse disease progression by decades.
Doudna: Epigenome editing offers reversible, safer path to common disease treatment vs permanent CRISPR
Scribe's epigenome editing modifies protein expression without altering DNA sequence, enabling one-time therapies for prevalent conditions like cardiovascular disease with a safety profile broad enough for mass deployment, representing a strategic shift from rare-disease gene editing to preventive medicine.
Engineered gene drives can eliminate invasive pests (screwworm, rats, ticks) in months rather than years, avoiding billions in chemical control costs and ecological damage, but deployment hinges on regulatory approval.
Multiplex genome editing at scale enables de-extinction and human germline applications
Colossal has pushed multiplex editing from 5-7 edits to hundreds, with a path to thousands, proving a scalable genome engineering platform that spans de-extinction, invasive species control, and potential human genetic disease correction.
De-extinction toolkit enables genome engineering at scale with applications across invasive species, human health, and novel materials
The same platform built for woolly mammoth de-extinction (multiplex editing, artificial wombs, computational genomics) solves half-trillion-dollar invasive species problems via gene drives, enables germline editing for genetic diseases, and creates lab-grown animal products (mammoth hair follicles) for luxury materials.
Ex vivo organ perfusion enables treatment of organs outside the body before transplant
Bloodless perfusion solutions keep donor organs viable at body temperature, allowing drug treatment of organs ex vivo (e.g., reversing fatty liver) before reimplantation — a platform applicable to transplant and eventually in situ organ therapy.
epI-editing offers non-permanent, repeatable gene therapy for mass-market cardiovascular disease
Unlike CRISPR's permanent DNA cuts, epI-editing modulates protein production reversibly, dramatically improving safety profile for chronic conditions like high LDL; enables one-time treatment replacing daily statins with broader patient eligibility.
iNKT cells emerge as third immunotherapy pillar combining innate and adaptive immunity
Invariant natural killer T cells target lipid antigens independent of MHC, traffic natively to dense tumor stroma, and reboot both innate and adaptive immune branches, potentially creating a scalable platform across solid tumors and inflammatory conditions.
Base editing embryos demonstrated: PCSK9 and hemoglobin editing in vitro, jurisdiction arbitrage inevitable
Columbia researchers successfully base-edited PCSK9 (LDL) and HBG (hemoglobin) genes in embryos. Base editing (single-nucleotide swaps, low error) superior to CRISPR. 80% Americans support disease prevention editing; enhancement boundary blurry. Jurisdiction arbitrage (Caribbean clinics) will bypass local bans. Nucleus offering polygenic embryo selection today.
Cell therapy completes the biology stack as the ultimate write layer for cellular dysfunction
When read/interpret layers fail due to broken cellular machinery, cell therapy provides new cells that execute healthy functions, representing the foundational write capability in the biology stack that enables the full read-interpret-write loop to function.
Gene editing is the hardware layer beyond peptide software
Peptides are reversible code; gene editing permanently rewrites the hardware. Recent congenital deafness reversal via gene editing proves the concept. The same data-network dynamic applies: customers will pay for curative outcomes, not the editing tool, and the dominant longitudinal data network will control the intelligence layer.
Verve's PCSK9 base editing proves one-shot in vivo gene editing can cure chronic disease
Single-infusion CRISPR base editing delivered via mRNA LNP achieves durable 62% LDL reduction, validating a modality applicable to thousands of genetic targets identified from human natural variants.
Mesenchymal stem cells and engineered NK cells emerge as platform therapies for neurodegeneration and cancer
Young bone marrow-derived mesenchymal stem cells (Lomecel-B) repair blood-brain barrier and clear amyloid in Alzheimer's, while IL-15 superagonist-expanded NK cells can be engineered to target tumors, viruses, and bacteria, creating reusable cellular platforms.
Gene editing identified as next major category after peptides, 10-year horizon
After peptides run their course (many years), gene-based therapies could surpass signaling-based therapies in effectiveness. Barriers: higher risk, ethical questions, science not yet mature. Companies like Moderna may have mRNA applications. Represents next frontier of wellness optimization beyond peptide signaling modulation.
Clinical trials demonstrate gene editing can fix genetic typos to restore hearing, while mesenchymal stem cells (Lomecel-B) act as local factories secreting factors that repair blood-brain barrier, clear amyloid, and modulate immunity in Alzheimer's.
Korean researchers demonstrate remote gene switching via household EM fields, opening bio-AI interface frontier
Engineered protein channels activated by 60Hz electromagnetic fields (standard wall current) enable non-invasive, remote control of gene expression; demonstrated aging reversal in mice via Yamanaka factors suggests a future where AI-designed biologics are triggered by ambient EM environments.